Cytek BioSciences Inc (CTKB)

NASD · Healthcare · Medical Devices · USA

Cytek BioSciences Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Cytek BioSciences develops cell analysis instruments using Full Spectrum Profiling technology to detect fluorescent signatures on single cells with high sensitivity and multiplexing. The company serves pharmaceutical, biopharma, academic research, and contract research organizations with analyzers, software, reagents, and services. It also offers conventional flow and imaging cytometry instruments through Amnis and Guava brands.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Cytek BioSciences Inc stock.

Our verdict on CTKB

Overvalued: intrinsic value $2.08 per share, market price $5.70, margin of safety -173.9% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $2.08; the price of $5.70 is 174% above that value.

ETFs with the most weight in CTKB

17 more funds hold it; the full list is part of the paid plan.

More on CTKB

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than CTKB in Medical Devices

42 more in this industry show a wider margin of safety.

Is CTKB undervalued or overvalued?

CTKB is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $2.08; the price of $5.70 is 174% above that value.

What is the intrinsic value of CTKB?

$2.08 per share (as of the 2026-11-17 close), against a market price of $5.70. That is a margin of safety of -173.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.